NO326899B1 - Antibakterielt protein samt anvendelser derav, terapeutisk formulering, polynukleotid og isolert organisme. - Google Patents

Antibakterielt protein samt anvendelser derav, terapeutisk formulering, polynukleotid og isolert organisme. Download PDF

Info

Publication number: NO326899B1
Authority: NO; Norway
Prior art keywords: therapeutic formulation; organism; protein; salivaricin; formulation according
Prior art date: 1999-10-12

Application number

NO20013905A

Other languages

English (en)

Norwegian (no)

Other versions

NO20013905L (no

NO20013905D0 (no

Inventor

John Robert Tagg

Karen Patricia Dierksen

Mathew Upton

Original Assignee

Blis Technologies Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-12

Filing date

2001-08-10

Publication date

2009-03-16

2001-08-10 Application filed by Blis Technologies Ltd filed Critical Blis Technologies Ltd

2001-08-10 Publication of NO20013905D0 publication Critical patent/NO20013905D0/no

2001-10-10 Publication of NO20013905L publication Critical patent/NO20013905L/no

2009-03-16 Publication of NO326899B1 publication Critical patent/NO326899B1/no

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 59
102000004169 proteins and genes Human genes 0.000 title claims abstract description 54
239000000203 mixture Substances 0.000 title claims abstract description 45
238000009472 formulation Methods 0.000 title claims abstract description 43
230000001225 therapeutic effect Effects 0.000 title claims abstract description 38
230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 14
108091033319 polynucleotide Proteins 0.000 title claims description 10
239000002157 polynucleotide Substances 0.000 title claims description 10
102000040430 polynucleotide Human genes 0.000 title claims description 10
108700018795 salivaricin A Proteins 0.000 claims abstract description 54
150000001413 amino acids Chemical class 0.000 claims description 28
241000194024 Streptococcus salivarius Species 0.000 claims description 25
CUHKVBVNLQPDQC-UHFFFAOYSA-N 3-[2,4,6,8-tetramethyl-4,6,8-tris(3-prop-2-enoyloxypropyl)-1,3,5,7,2,4,6,8-tetraoxatetrasilocan-2-yl]propyl prop-2-enoate Chemical compound C=CC(=O)OCCC[Si]1(C)O[Si](C)(CCCOC(=O)C=C)O[Si](C)(CCCOC(=O)C=C)O[Si](C)(CCCOC(=O)C=C)O1 CUHKVBVNLQPDQC-UHFFFAOYSA-N 0.000 claims description 15
238000006467 substitution reaction Methods 0.000 claims description 13
230000002401 inhibitory effect Effects 0.000 claims description 12
239000003242 anti bacterial agent Substances 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 10
241000894006 Bacteria Species 0.000 claims description 9
235000013361 beverage Nutrition 0.000 claims description 9
235000013336 milk Nutrition 0.000 claims description 9
239000008267 milk Substances 0.000 claims description 9
210000004080 milk Anatomy 0.000 claims description 9
210000002345 respiratory system Anatomy 0.000 claims description 8
230000001580 bacterial effect Effects 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 6
238000003780 insertion Methods 0.000 claims description 6
230000037431 insertion Effects 0.000 claims description 6
230000003115 biocidal effect Effects 0.000 claims description 5
235000009508 confectionery Nutrition 0.000 claims description 5
238000012217 deletion Methods 0.000 claims description 5
230000037430 deletion Effects 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 4
239000000843 powder Substances 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
229940112822 chewing gum Drugs 0.000 claims description 3
235000015218 chewing gum Nutrition 0.000 claims description 3
-1 gargle Substances 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
108091026890 Coding region Proteins 0.000 claims description 2
230000002368 bacteriocinic effect Effects 0.000 claims description 2
235000015895 biscuits Nutrition 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
235000013351 cheese Nutrition 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
235000019541 flavored milk drink Nutrition 0.000 claims description 2
239000002324 mouth wash Substances 0.000 claims description 2
239000007921 spray Substances 0.000 claims description 2
239000006188 syrup Substances 0.000 claims description 2
235000020357 syrup Nutrition 0.000 claims description 2
229940034610 toothpaste Drugs 0.000 claims description 2
239000000606 toothpaste Substances 0.000 claims description 2
235000013618 yogurt Nutrition 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 2
235000013365 dairy product Nutrition 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
239000007937 lozenge Substances 0.000 claims 1
229940051866 mouthwash Drugs 0.000 claims 1
WYCRECCWGWCUHS-KABIMGDMSA-N C([C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)C(C)C)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O)C1=CN=CN1 Chemical compound C([C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)C(C)C)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O)C1=CN=CN1 WYCRECCWGWCUHS-KABIMGDMSA-N 0.000 abstract description 39
241000193996 Streptococcus pyogenes Species 0.000 abstract description 10
206010061372 Streptococcal infection Diseases 0.000 abstract description 5
235000018102 proteins Nutrition 0.000 description 36
108020004414 DNA Proteins 0.000 description 27
108010062877 Bacteriocins Proteins 0.000 description 18
238000000034 method Methods 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
230000000694 effects Effects 0.000 description 12
239000012634 fragment Substances 0.000 description 12
235000001014 amino acid Nutrition 0.000 description 11
229940024606 amino acid Drugs 0.000 description 10
229920001817 Agar Polymers 0.000 description 9
238000012360 testing method Methods 0.000 description 9
239000008272 agar Substances 0.000 description 8
239000013599 cloning vector Substances 0.000 description 8
239000002773 nucleotide Substances 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
239000013598 vector Substances 0.000 description 8
238000010367 cloning Methods 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
239000000523 sample Substances 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
238000011534 incubation Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
238000000746 purification Methods 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
239000011550 stock solution Substances 0.000 description 5
238000011282 treatment Methods 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
241000194017 Streptococcus Species 0.000 description 4
230000003385 bacteriostatic effect Effects 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000011835 investigation Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241001625930 Luria Species 0.000 description 3
235000015076 Shorea robusta Nutrition 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
239000007382 columbia agar Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
241000192125 Firmicutes Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
241000191938 Micrococcus luteus Species 0.000 description 2
108010053775 Nisin Proteins 0.000 description 2
NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000193987 Streptococcus sobrinus Species 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
208000002925 dental caries Diseases 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000010828 elution Methods 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000004309 nisin Substances 0.000 description 2
235000010297 nisin Nutrition 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
241000894007 species Species 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108050009160 DNA polymerase 1 Proteins 0.000 description 1
101100234002 Drosophila melanogaster Shal gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
206010018366 Glomerulonephritis acute Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000191953 Kocuria varians Species 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
206010034839 Pharyngitis streptococcal Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
238000012181 QIAquick gel extraction kit Methods 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010039587 Scarlet Fever Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
244000166071 Shorea robusta Species 0.000 description 1
241000888288 Streptococcus salivarius K12 Species 0.000 description 1
241000194020 Streptococcus thermophilus Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
231100000851 acute glomerulonephritis Toxicity 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000006161 blood agar Substances 0.000 description 1
230000001680 brushing effect Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
238000012219 cassette mutagenesis Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000005452 food preservative Substances 0.000 description 1
235000019249 food preservative Nutrition 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
230000036039 immunity Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000001038 ionspray mass spectrometry Methods 0.000 description 1
238000010829 isocratic elution Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
108010087689 lacticin 481 Proteins 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
208000016765 streptococcal sore throat Diseases 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000010257 thawing Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
239000004474 valine Substances 0.000 description 1
108010005406 variacin Proteins 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Otolaryngology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Jellies, Jams, And Syrups (AREA)
Peptides Or Proteins (AREA)
Confectionery (AREA)
Dairy Products (AREA)
Medicinal Preparation (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20013905A 1999-10-12 2001-08-10 Antibakterielt protein samt anvendelser derav, terapeutisk formulering, polynukleotid og isolert organisme. NO326899B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NZ50026199		1999-10-12
PCT/NZ2000/000197 WO2001027143A1 (en)	1999-10-12	2000-10-12	Lantibiotic

Publications (3)

Publication Number	Publication Date
NO20013905D0 NO20013905D0 (no)	2001-08-10
NO20013905L NO20013905L (no)	2001-10-10
NO326899B1 true NO326899B1 (no)	2009-03-16

Family

ID=19927569

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20013905A NO326899B1 (no)	1999-10-12	2001-08-10	Antibakterielt protein samt anvendelser derav, terapeutisk formulering, polynukleotid og isolert organisme.

Country Status (15)

Country	Link
US (2)	US6773912B1 (de)
EP (1)	EP1169340B1 (de)
JP (1)	JP3673497B2 (de)
AT (1)	ATE362481T1 (de)
AU (1)	AU772224B2 (de)
BR (1)	BR0014740A (de)
CA (1)	CA2363713C (de)
DE (1)	DE60034879T8 (de)
DK (1)	DK1169340T3 (de)
ES (1)	ES2286038T3 (de)
HK (1)	HK1039622B (de)
NO (1)	NO326899B1 (de)
PL (1)	PL206441B1 (de)
RU (1)	RU2279481C2 (de)
WO (1)	WO2001027143A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1483366T3 (da) *	2002-02-22	2010-08-09	Blis Technologies Ltd	Antimikrobiel sammensætning
US6861236B2 (en)	2002-05-24	2005-03-01	Applied Nanosystems B.V.	Export and modification of (poly)peptides in the lantibiotic way
WO2004072272A1 (en) *	2003-02-14	2004-08-26	Blis Technologies Limited	Bacterial compositions
WO2005007178A1 (en) *	2003-07-18	2005-01-27	Blis Technologies Limited	Treatment of malodour
US20080032924A1 (en) *	2004-02-24	2008-02-07	Peter David East	Antifungal Peptides
WO2007070518A2 (en) *	2005-12-13	2007-06-21	The Trustees Of The University Of Pennsylvania	Bacteria-derived blis for treatment of acne
FR2905268B1 (fr) *	2006-09-01	2009-01-23	Unither Dev Soc Par Actions Si	Substitut salivaire
RU2441915C9 (ru) *	2007-08-03	2012-06-20	Сентинелла Фармасьютикалс, Инк.	Гены и белки для биосинтеза лантибиотика 107891
GB0921995D0 (en) *	2009-12-17	2010-02-03	Univ Manchester	Antimicrobial peptides
RS54837B1 (sr) *	2010-04-07	2016-10-31	Dmg Italia Srl	Upotreba streptococcus salivarius u lečenju hroničnih infekcija respiratornog trakta
DE102012203547A1 (de) *	2012-03-07	2013-09-12	Robert Bosch Gesellschaft Für Medizinische Forschung Mbh	Antimikrobielle Peptide
CA2783414A1 (en) *	2012-07-22	2014-01-22	Integral Medical Inc.	Probiotic composition
CN104398537A (zh) *	2014-11-17	2015-03-11	南京灿辰微生物科技有限公司	一种口腔益生菌组合物
CN111227035A (zh) *	2018-11-28	2020-06-05	内蒙古伊利实业集团股份有限公司	一种含益生菌组合物的发酵乳及其制备方法
CN112391305B (zh) *	2019-08-15	2023-01-13	上海交通大学	唾液链球菌f286及其用途
WO2023053073A1 (en) *	2021-09-30	2023-04-06	Blis Technologies Limited	Probiotic enhancers and uses thereof
CN117304334A (zh) *	2023-04-25	2023-12-29	大连医科大学	一种唾液链球菌抗菌肽及其制备方法和应用
WO2025132965A1 (en)	2023-12-21	2025-06-26	Reichardt Elisabeth	Formulations and devices comprising lantibiotic-producing bacteria

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3925160A (en) *	1974-09-26	1975-12-09	Univ Creighton	Method of producing an antibiotic
JPS615022A (ja) *	1984-06-19	1986-01-10	Advance Res & Dev Co Ltd	腸内細菌叢改善剤
SE463349B (sv)	1989-02-15	1990-11-12	Grahn Eva E	Farmaceutiskt preparat foer profylax mot och/eller behandling av beta-streptokockinducerad tonsillit
JPH054927A (ja) *	1991-06-28	1993-01-14	Aizo Matsushiro	乳酸菌含有組成物及びその製造方法
US5872001A (en)	1994-04-20	1999-02-16	Uab Research Foundation	Lanthionine antibiotic compositions and methods

2000
- 2000-10-12 DE DE60034879T patent/DE60034879T8/de active Active
- 2000-10-12 WO PCT/NZ2000/000197 patent/WO2001027143A1/en not_active Ceased
- 2000-10-12 BR BR0014740-0A patent/BR0014740A/pt not_active Application Discontinuation
- 2000-10-12 US US09/913,763 patent/US6773912B1/en not_active Expired - Lifetime
- 2000-10-12 HK HK02100947.2A patent/HK1039622B/en unknown
- 2000-10-12 JP JP2001530361A patent/JP3673497B2/ja not_active Expired - Fee Related
- 2000-10-12 DK DK00970338T patent/DK1169340T3/da active
- 2000-10-12 AU AU79737/00A patent/AU772224B2/en not_active Expired
- 2000-10-12 RU RU2002112327/13A patent/RU2279481C2/ru active
- 2000-10-12 EP EP00970338A patent/EP1169340B1/de not_active Expired - Lifetime
- 2000-10-12 ES ES00970338T patent/ES2286038T3/es not_active Expired - Lifetime
- 2000-10-12 CA CA002363713A patent/CA2363713C/en not_active Expired - Lifetime
- 2000-10-12 PL PL364771A patent/PL206441B1/pl unknown
- 2000-10-12 AT AT00970338T patent/ATE362481T1/de not_active IP Right Cessation
2001
- 2001-08-10 NO NO20013905A patent/NO326899B1/no not_active IP Right Cessation
2004
- 2004-05-19 US US10/848,750 patent/US20040232205A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60034879T2 (de)	2008-02-07
EP1169340A1 (de)	2002-01-09
NO20013905L (no)	2001-10-10
DK1169340T3 (da)	2007-09-24
ATE362481T1 (de)	2007-06-15
CA2363713C (en)	2007-11-06
DE60034879T8 (de)	2008-07-03
NO20013905D0 (no)	2001-08-10
JP2003516123A (ja)	2003-05-13
US20040232205A1 (en)	2004-11-25
RU2279481C2 (ru)	2006-07-10
EP1169340B1 (de)	2007-05-16
PL364771A1 (en)	2004-12-13
AU772224B2 (en)	2004-04-22
WO2001027143A1 (en)	2001-04-19
CA2363713A1 (en)	2001-04-19
AU7973700A (en)	2001-04-23
HK1039622A1 (en)	2002-05-03
PL206441B1 (pl)	2010-08-31
JP3673497B2 (ja)	2005-07-20
US6773912B1 (en)	2004-08-10
ES2286038T3 (es)	2007-12-01
HK1039622B (en)	2007-10-18
BR0014740A (pt)	2002-06-18
DE60034879D1 (en)	2007-06-28
EP1169340A4 (de)	2005-06-08

Legal Events

Date	Code	Title	Description
2020-11-09	MK1K	Patent expired

Publication	Publication Date	Title
Aymerich et al.	1996	Biochemical and genetic characterization of enterocin A from Enterococcus faecium, a new antilisterial bacteriocin in the pediocin family of bacteriocins
EP1169340B1 (de)	2007-05-16	Lantibiotikum
RU2172324C2 (ru)	2001-08-20	Бактериоцин, способ его получения, штамм micrococcus varians, нуклеотидный фрагмент, сигнальный пептид
US6391285B1 (en)	2002-05-21	Antimicrobial polypeptide and methods of use
WO2016176729A1 (en)	2016-11-10	Bacteriocin polypeptides and uses thereof
MXPA96003127A (en)	1997-06-01	Bacterioc
US5231165A (en)	1993-07-27	Bacteriocin from lactococcus lactis subspecies lactis
Liu et al.	2015	Properties of a bacteriocin produced by Bacillus subtilis EMD4 isolated from ganjang (soy sauce)
US7238515B2 (en)	2007-07-03	Anti-Listeria bacteriocin
AU2006333246B2 (en)	2012-02-02	Bacteriocin inducer peptides
US5232849A (en)	1993-08-03	Bacteriocin from lactococcus lactis subspecies lactis
US7067125B2 (en)	2006-06-27	Antimicrobial polypeptides and methods of use
WO1997023619A1 (en)	1997-07-03	Sequences coding for new bacteriocins